Literature DB >> 27622386

Early treatment with reverse transcriptase inhibitors significantly suppresses peak plasma IFNα in vivo during acute simian immunodeficiency virus infection.

Jeffy George1, Lynnsey Renn2, Daniela Verthelyi3, Mario Roederer4, Ronald L Rabin2, Joseph J Mattapallil5.   

Abstract

Innate interferons (IFN) are comprised of multiple Type I and III subtypes. The in vivo kinetics of subtype responses during human immunodeficiency virus (HIV) infection is not well defined. Using the acute simian immunodeficiency virus (SIV) infection model, we show that plasma IFNα levels peak at day 10 post-infection (pi) after which they rapidly declined. The mRNA expression of Type I and III IFN subtypes were significantly elevated in the lymph nodes (LN) at day 10 pi. Though the expression levels of all subtypes declined by day 14-31 pi, numerous subtypes remained elevated suggesting that ongoing viral replication in LN continues to drive induction of these subtypes. Interestingly, treatment with reverse transcriptase (RT) inhibitors at day 7 pi significantly suppressed plasma IFNα responses by day 10 pi that significantly correlated with cell-associated SIV DNA loads suggesting that RT byproducts such as viral DNA likely plays a role in driving IFN responses during acute SIV infection. Quantification of Type I and III subtype transcripts in sorted subsets of LN CD4+ and CD8+ T cells, CD14+/CD14- monocytes/macrophages, and total CD11c/CD123+ dendritic cells (DC) at day 10 pi showed that DC expressed ∼3-4 log more subtype transcripts as compared to the other subsets. Taken together, our results provide new insights into the kinetics of innate interferon responses during early stages of infection, and provide evidence that DC's are a major in vivo source of innate IFN during acute SIV infection. Published by Elsevier Inc.

Entities:  

Keywords:  Dendritic cells; HIV; IFNα; IFNβ; Mucosa; SIV; Subtypes

Mesh:

Substances:

Year:  2016        PMID: 27622386     DOI: 10.1016/j.cellimm.2016.09.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

1.  A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis.

Authors:  Stephanie M Dillon; Kejun Guo; Gregory L Austin; Sara Gianella; Phillip A Engen; Ece A Mutlu; John Losurdo; Garth Swanson; Prachi Chakradeo; Ali Keshavarzian; Alan L Landay; Mario L Santiago; Cara C Wilson
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177

Review 2.  Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional Cure.

Authors:  Jeffy George; Joseph J Mattapallil
Journal:  Front Immunol       Date:  2018-02-22       Impact factor: 7.561

3.  Chronic simian immunodeficiency virus infection is associated with contrasting phenotypes of dysfunctional Bcl6+ germinal center B cells or Bcl6- Bcl2+ non-germinal center B cells.

Authors:  Olusegun O Onabajo; Mark G Lewis; Joseph J Mattapallil
Journal:  J Cell Mol Med       Date:  2018-09-06       Impact factor: 5.310

Review 4.  Gut Microbiome Homeostasis and the CD4 T- Follicular Helper Cell IgA Axis in Human Immunodeficiency Virus Infection.

Authors:  Olusegun O Onabajo; Joseph J Mattapallil
Journal:  Front Immunol       Date:  2021-03-19       Impact factor: 7.561

5.  Gender differences in innate responses and gene expression profiles in memory CD4 T cells are apparent very early during acute simian immunodeficiency virus infection.

Authors:  Jeffy George; Ryan C Johnson; Mary J Mattapallil; Lynnsey Renn; Ronald Rabin; D Scott Merrell; Joseph J Mattapallil
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

6.  Microbial Dysbiosis During Simian Immunodeficiency Virus Infection is Partially Reverted with Combination Anti-retroviral Therapy.

Authors:  Faith C Blum; Britney L Hardy; Kimberly A Bishop-Lilly; Kenneth G Frey; Theron Hamilton; James B Whitney; Mark G Lewis; D Scott Merrell; Joseph J Mattapallil
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.